一种基于药物监测数据的方法,以揭示检查点免疫疗法后高致命性不良事件
Zhen Sun1, Xuan Deng2, Jianglong Guo1
1State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200032, China.
免疫检查点抑制剂 (ICI) 可以改善癌症治疗,但会导致不良事件 (AE). 这项研究确定了来自ICI治疗的63种高死亡率的副作用,如肺部疾病和肝功能衰竭,需要密切监测以减少患者死亡率.
科学领域:
- 在瘤学瘤学.
- 药物监督 药物监督 药物监督
- 免疫治疗是一种免疫疗法.
背景情况:
- 免疫检查点抑制剂 (ICI) 已经彻底改变了癌症治疗.
- 然而,ICI与一系列与治疗相关的不良事件 (AE) 有关.
- 识别高死亡率的AE对于患者安全至关重要.
研究的目的:
- 引入一种修改后的药物监测方法来识别"与ICI相关的高死亡率的AE".
- 确定这些严重并发症的类型和患病率.
- 为主动监测和干预策略提供信息.
主要方法:
- 从FDA的AE报告系统 (148,972例) 和世卫组织VigiBase (142,645例) 分析大规模的药监数据.
- 确定在ICI治疗期间不成比例地提高死亡率的特定AE类型.
- 使用额外的临床数据集对发现进行验证.
主要成果:
- 确定了63种不同类型的ICI相关高死亡率的AE.
- 例如包括间歇性肺病,肌肉炎和肝功能衰竭.
- 经历这些副作用的患者与其他副作用 (10.66%) 相比,死亡率明显高 (36.25%).
结论:
- 该研究成功地确定了关键的ICI相关高死亡率的AE.
- 这些发现强调了需要提高临床警的必要性.
- 积极的监测和有针对性的干预措施对于减轻ICI相关的死亡风险至关重要.
更多相关视频
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023
07:40Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021
相关概念视频
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Therapeutic Drug Monitoring: Affecting Factors
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Therapeutic Drug Monitoring: Overview and Classification
Therapeutic Drug Monitoring: Drug Analysis Methods
Pharmacogenomics: Identification of New Drug Targets
